In MRL/lpr mice, systemic administration of apoVs reduced lymphoproliferation, decreased IFN-γ+ CD4+ T cells, increased Foxp3+ regulatory T cells, and alleviated the inflammatory activity of lupus and arthritis. Here, CD4 is linked to systemic lupus erythematosus.